印度的制药出口在2025年9月达到2.62B美元,通过监管和制造业升级支持了美国药物进口的31%。 India’s pharma exports hit $2.62B in Sept 2025, supporting 31% of U.S. drug imports amid regulatory and manufacturing upgrades.

印度商务部长Goyal(Piyush Goyal)与制药业领导人会面,讨论增长战略、监管改革、创新和制造业扩张。 India’s Commerce Minister Piyush Goyal met with pharmaceutical industry leaders to discuss growth strategies, regulatory reforms, innovation, and manufacturing expansion. 会议强调了印度在全球非专利药品和活性药品成分出口方面的强势地位,这些出口不是拟议中的美国对品牌药品征收关税的目标。 The meeting highlighted India’s strong position in global generics and active pharmaceutical ingredient exports, which are not targeted by proposed U.S. tariffs on branded drugs. 印度供应美国药品进口的31%以上,非专利药品的47%以上,2025年9月的出口总额达26.2亿美元。 India supplies over 31% of U.S. pharmaceutical imports and 47% of its generic drugs, with September 2025 exports totaling $2.62 billion. 政府加强监管和制造业的努力被认为是在全球贸易不确定的情况下维持出口增长的关键。 Government efforts to strengthen regulation and manufacturing are seen as key to sustaining export growth amid global trade uncertainties.